{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:10:23Z","timestamp":1791227423473,"version":"4.1.0"},"reference-count":132,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of patients, despite platinum-based combination chemotherapy, the majority of patients affected by non-small-cell lung cancer (NSCLC) did not live longer than one year. With deeper understanding of tumor molecular biology, treatment of NSCLC has progressively entered the era of treatment customization according to tumor molecular characteristics, as well as histology. All this information allowed the development of personalized molecular targeted therapies. A series of studies have shown that, in some cases, cancer cells can grow and survive as result of the presence of a single driver genomic abnormality. This phenomenon, called oncogene-addiction, more often occurs in adenocarcinoma histology, in non-smokers (except BRAF mutations, also frequent in smoking patients), young, and female patients. Several different driver mutations have been identified and many studies have clearly shown that upfront TKI monotherapy may improve the overall outcome of these patients. The greater efficacy of these drugs is also associated with a better tolerability and safety than chemotherapy, with fewer side effects and an extremely good compliance to treatment. The most frequent oncogene-addicted disease is represented by those tumors carrying a mutation of the epidermal growth factor receptor (EGFR). The development of first, second and third generation TKIs against EGFR mutations have dramatically changed the prognosis of these patients. Currently, osimertinib (which demonstrated to improve efficacy with a better tolerability in comparison with first-generation TKIs) is considered the best treatment option for patients affected by NSCLC harboring a common EGFR mutation. EML4-ALK-driven disease (which gene re-arrangement occurs in 3\u20137% of NSCLC), has demonstrated to be significantly targeted by specific TKIs, which have improved outcome in comparison with chemotherapy. To date, alectinib is considered the best treatment option for these patients, with other newer agents upcoming. Other additional driver abnormalities, such as ROS1, BRAF, MET, RET and NTRK, have been identified as a target mirroring peculiar vulnerability to specific agents. Oncogene-addicted disease typically has a low early resistance rate, but late acquired resistance always develops and therefore therapy needs to be changed when progression occurs. In this narrative review, the state of art of scientific literature about targeted therapy options in oncogene-addicted disease is summarized and critically discussed. We also aim to analyze future perspectives to maximize benefits for this subgroup of patients.<\/jats:p>","DOI":"10.3390\/cancers12051196","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T11:26:00Z","timestamp":1588937160000},"page":"1196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives"],"prefix":"10.3390","volume":"12","author":[{"given":"Miriam Grazia","family":"Ferrara","sequence":"first","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Noia","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Oncologia medica, Humanitas Gavazzeni, 24125 Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-9876","authenticated-orcid":false,"given":"Ettore","family":"D\u2019Argento","sequence":"additional","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4546-547X","authenticated-orcid":false,"given":"Emanuele","family":"Vita","sequence":"additional","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Damiano","sequence":"additional","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cannella","sequence":"additional","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ribelli","sequence":"additional","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University and Hospital Trust of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[{"name":"Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University and Hospital Trust of Verona, 37126 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-704X","authenticated-orcid":false,"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[{"name":"Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Medical Oncology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"New Engl. J. Med."},{"key":"ref_3","first-page":"25","article-title":"Prognostic factors for survival in patients with inoperable lung cancer","volume":"65","author":"Stanley","year":"1980","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","article-title":"Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer","volume":"16","author":"Tan","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"ref_6","first-page":"2696","article-title":"Disorders in cell circuitry associated with multistage carcinogenesis: Exploitable targets for cancer prevention and therapy","volume":"3","author":"Weinstein","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Addiction to oncogenes\u2014The Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ncponc0558","article-title":"Mechanisms of disease: Oncogene addiction\u2014A rationale for molecular targeting in cancer therapy","volume":"3","author":"Weinstein","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","article-title":"Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1556-0864(16)30171-X","article-title":"57O\u2014Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-na\u00efve patients (pts) with EGFR mutant NSCLC","volume":"11","author":"Gibbons","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","unstructured":"(2020, April 21). A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02013219."},{"key":"ref_15","unstructured":"(2020, April 21). Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients (GEFTREM), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02040064."},{"key":"ref_16","unstructured":"(2020, March 05). Study of Nivolumab (BMS-936558) in Combination With Gemcitabine\/Cisplatin, Pemetrexed\/Cisplatin, Carboplatin\/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB\/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01454102."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation\u2014Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtho.2018.04.025","article-title":"Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients","volume":"13","author":"Garassino","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"20","author":"Gasco","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.18632\/oncotarget.3727","article-title":"Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma","volume":"6","author":"Bria","year":"2015","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2006.04.022","article-title":"The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies","volume":"9","author":"Ji","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"New Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdt012","article-title":"Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)","volume":"24","author":"Chen","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1586\/14737140.2014.983083","article-title":"Afatinib and lung cancer","volume":"14","author":"Jain","year":"2014","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-07-2232","article-title":"Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor","volume":"7","author":"Gonzales","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: First-generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bjc.2016.456","article-title":"A phase III randomised controlled trial of erlotinib vs. gefitinib in advanced non-small cell lung cancer with EGFR mutations","volume":"116","author":"Yang","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/ijc.32015","article-title":"Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation","volume":"144","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component","volume":"35","author":"Yang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"v460","DOI":"10.1093\/annonc\/mdx380.050","article-title":"Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies","volume":"28","author":"Mitsudomi","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e20625","DOI":"10.1200\/JCO.2017.35.15_suppl.e20625","article-title":"Detecting T790M mutation of tissue and plasma ctDNA samples by ARMS in EGFR-mutant NSCLC patients after disease progression","volume":"35","author":"Wu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/1078-0432.CCR-18-3325","article-title":"Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer","volume":"25","author":"Planchard","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","article-title":"Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer","volume":"68","author":"Choi","year":"2008","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-08-1018","article-title":"Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts","volume":"14","author":"Takeuchi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S7533","DOI":"10.1200\/jco.2012.30.15_suppl.7533","article-title":"Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC)","volume":"30","author":"Kim","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"New Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/cas.13721","article-title":"Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9","volume":"109","author":"Hida","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: Results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): A randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_95","unstructured":"(2020, April 24). Biomarker\/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03737994."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.jtho.2016.11.429","article-title":"MA07.06 Crizotinib in ROS1 rearranged or MET deregulated NSCLC: Preliminary results of the METROS trial","volume":"12","author":"Landi","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: A multicentre, open-label, single-arm, phase 1-2 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"S9011","DOI":"10.1200\/JCO.2019.37.15_suppl.9011","article-title":"Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","article-title":"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer","volume":"19","author":"Cardarella","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: A single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"New Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_109","first-page":"S108","article-title":"Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"4","author":"Drilon","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S9004","DOI":"10.1200\/JCO.2019.37.15_suppl.9004","article-title":"Capmatinib (INC280) in MET\u0394ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study","volume":"37","author":"Wolf","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"S9005","DOI":"10.1200\/JCO.2019.37.15_suppl.9005","article-title":"Phase II study of tepotinib in NSCLC patients with METex14 mutations","volume":"37","author":"Paik","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jtho.2018.08.304","article-title":"Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with RET fusion+ non-small cell lung cancer","volume":"13","author":"Oxnard","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_117","unstructured":"Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., and Horiike, A. (2019, January 7\u201310). Registrational results of LIBRETTO-001: A phase1\/2 trial of Selpercatinib (LOXO-292) in patients with RET fusion-positive lung cancers. Proceedings of the World Conference in Lung Cancer, Barcelona, Spain."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)","volume":"37","author":"Gainor","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(01)00530-4","article-title":"Trk receptor tyrosine kinases: A bridge between cancer and neural development","volume":"169","author":"Nakagawara","year":"2001","journal-title":"Cancer Lett."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jtho.2018.08.897","article-title":"Rapid, robust and durable responses to Larotrectinib in patients with TRK fusion non-small cell lung Cancer","volume":"13","author":"Farago","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/2159-8290.CD-17-0507","article-title":"A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"viii713","DOI":"10.1093\/annonc\/mdy424.017","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001","volume":"29","author":"Demetri","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: Phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e9070","DOI":"10.1200\/JCO.2017.35.15_suppl.9070","article-title":"A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial","volume":"35","author":"Smit","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41416-018-0194-7","article-title":"Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment","volume":"119","author":"Jebbink","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-17-1875","article-title":"Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib","volume":"24","author":"Liu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/annonc\/mdy542","article-title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:26:56Z","timestamp":1760174816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":132,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051196"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051196","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]}}}